Liver disease : Wegovy injection is approved for MASH, a serious liver disease linked to fat buildup in the liver
Active gallbladder disease Wegovy is linked to a slightly increased risk of gallstones and gallbladder inflammation (cholecystitis)
Other reported effects Beyond GI symptoms, clinical trials noted several other effects worth monitoring: Increased heart rate: A small, dose-dependent increase in resting heart rate was observed, consistent with what occurs with other GLP-1 agonists
This study yielded an interesting finding: no significant association was observed between vitamin B2 intake and hip fracture risk
The FDA decision to allow compounded semaglutide at standard doses was made based on semaglutide supply levels at the time
They shouldnt use any medications, drugs, or compounds that give them an unfair advantage